Read or listen to 5 expert commentaries providing global perspectives on emerging data in ovarian and endometrial cancers presented at the 2021 meetings of SGO, ASCO, IGCS, ESMO, and ESGO, and then download the slideset with all the key data.
This educational program is intended for clinicians practicing medicine outside of the United States.
In this podcast episode, listen to David Scott Miller, MD, FACOG, FACS, and Melissa M. Hardesty, MD, MPH, discuss new data for gynecologic cancers presented at the virtual ASCO 2021 annual meeting, including novel data for single-agent immunotherapy in patients with endometrial cancer, data for novel agents targeting the folate receptor-α in ovarian cancer, and data for a novel bifunctional fusion proteins cotargeting the TGF-β receptor and PD-L1 pathways in cervical cancers.
In this podcast episode, listen to Prof. Isabelle Ray-Coquard, MD, PhD, and Bernard Doger de Spéville, MD, PhD, discuss important new clinical trial data for endometrial and ovarian cancers presented at the virtual ESMO 2021 annual meeting.
In this podcast episode, listen to Nicole Concin, MD, PhD, as she highlights important clinical trial data for ovarian and endometrial cancers presented at the ESGO 2021 annual meeting.
In this podcast episode, listen to Ursula Matulonis, MD, and Jubilee Brown, MD, discuss new data for gynecological cancers presented at the virtual SGO 2021 meeting, including immunotherapy-based combinations for endometrial cancer and PARP inhibitors for BRCA-mutated ovarian cancers.
This podcast is intended for clinicians practicing medicine outside of the United States.
In this podcast episode, listen to Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, discuss practice‑changing data for gynecologic cancers presented at the virtual IGCS 2021 annual meeting, including novel data for single-agent and combination immunotherapy in patients with endometrial and cervical cancers, subanalyzes of exceptional responders to PARP inhibitors in ARIEL3, and timing for initiation of PARP inhibitor maintenance from the NORA trial.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.